Germline mutations in the RET proto-oncogene are seen in the majority of patients with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2 (MEN 2). The clinical subtypes of MEN 2 (MEN 2A, MEN 2B and familial MTC) all have medullary thyroid carcinoma, but vary in the involvement of pheochromocytoma, parathyroid adenoma/hyperplasia and developmental abnormalities. A single RET mutation, resulting in the substitution M918T, has been identi®ed in 94% of cases of MEN 2B (which consists of MTC, pheochromocytoma and developmental abnormalities). Here we report the identi®cation of a new germline RET mutation (A883F) in two de novo cases of MEN 2B. Identi®cation of this new mutation will contribute to understanding the molecular basis of MEN 2B, and will assist in the clinical management of families harbouring this mutation.
Introduction
Activating germline mutations in the RET receptor tyrosine kinase occur in 96% of patients with MEN 2 (Eng et al., 1996; reviewed in Ponder and Smith, 1996; Eng and Mulligan, 1997) . There are three clinical subtypes of MEN 2: MEN 2A, MEN 2B and familial MTC (FMTC) (Farndon et al., 1986; Schimke, 1984) which are de®ned by the tissues involved. Dierent RET mutations are associated with each clinical subtype.
MEN 2A consists of predisposition to medullary thyroid carcinoma (MTC), pheochromocytoma (in approximately 50% of cases) and parathyroid hyperplasia/adenoma (in approximately 25% of cases). FMTC consists of predisposition to MTC only. MEN 2B is similar to MEN 2A except that parathyroid disease is seldom if ever seen, and there are characteristic musculoskeletal and peripheral nerve abnormalities . Musculoskeletal abnormalities may include a long, thin body shape (resembling that of Marfan syndrome), pes cavus pectus excavatum, bi®d ribs and slipped femoral epiphyses. Peripheral nerve abnormalities may include hyperplasia of extrinsic autonomic nerve ®bres in the intestinal wall (resulting in disturbances of intestinal motility), disorganised nerve tissues resulting iǹ neuromas' which give rise to characteristically full lips and lumps on the tongue, and thickened corneal nerve ®bres.
Ninety-eight percent of MEN 2A cases are caused by mutation of one of ®ve conserved cysteine residues in the extracellular domain of RET (C609, 611, 618, 620, 634) (Eng et al., 1996; Ponder and Smith, 1996; Eng and Mulligan, 1997; Mulligan et al., 1993 Mulligan et al., , 1994 . Receptor tyrosine kinases are activated by dimerisation induced by ligand binding to the extracellular domain (Pawson and Schlessinger, 1993) . The ligand for RET is the neurotrophic factor GDNF associated with the membrane-bound protein GDNFRa (Durbec et al., 1996; Jing et al., 1996; Treanor et al., 1996; Trupp et al., 1996) . The cysteine codon mutations tested so far lead to ligand-independent RET activation by the formation of covalent disulphide-bonded homodimers (Santoro et al., 1995; Borrello et al., 1996; Asai et al., 1995) .
Eighty-eight percent of FMTC cases are caused by mutations similar to those seen in MEN 2A. In addition there have been seven families reported with mutations (E768D, V804L) in the intracellular kinase domain (Eng et al., , 1996 Eng and Mulligan, 1997; Bolino et al., 1995) . The mechanism of RET activation by these mutations is uncertain.
Ninety-four percent of MEN 2B cases (75 of 80 analysed) are caused by a single mutation (M918T) in the tyrosine kinase domain of RET (Eng et al., , 1996 Hofstra et al., 1994; Carlson et al., 1994 and this paper) . This mutation, which lies in the substrate binding pocket of the kinase domain (Hanks et al., 1988) leads to ligand-independent activation of RET by an uncertain mechanism, and also to altered tyrosine phosphorylation of the receptor and altered catalytic substrate speci®city (Santoro et al., 1995; Songyang et al., 1995; Liu et al., 1996) .
RET mutations have been found in the sporadic counterparts of the tumours found in MEN 2 Eng and Mulligan, 1997) . The MEN 2B-like mutation M918T occurs in approximately 40% of sporadic MTC. Other types of mutation do occur but are rare in sporadic MTC, and all types of mutation are rare in sporadic pheochromocytoma.
RET mutations are also found in some cases of dominantly inherited and sporadic Hirschsprung disease (Eng and Mulligan, 1997; Attie et al., 1995) . Hirschsprung disease is the congenital lack of intestinal autonomic nerve plexuses. Missense mutations have been shown fully or partially to inactivate the RET kinase Carlomagno et al., 1996; Lorenzo et al., 1997) , and many mutations lead to extreme truncations of the RET protein (Attie et al., 1995) . In addition, papillary thyroid carcinoma (PTC) is associated with RET activation by somatic rearrangement to create constitutively active chimeric proteins (reviewed in Pierotti et al., 1996) .
Activating mutations in the kinase domain of the receptor tyrosine kinases c-kit (D814Y; equivalent to RET codon 898) and FGFR3 (K650E; equivalent to RET codon 908) which also alter the catalytic substrate speci®city have recently been reported (Webster et al., 1996; Piao et al., 1996; Su et al., 1997) , and in the case of the c-kit mutation the substrate speci®city change is related to that seen in M918T-RET. Consequently we decided to analyse this region of RET (exon 15) in three cases of clinically clear MEN 2B (two de novo and one familial) which do not harbour the M918T mutation. No mutation in exon 15 was found in the familial case, in agreement with a previous report (Toogood et al., 1995) , but in both de novo cases the mutation A883F was identi®ed.
Results
Three patients with clinically clear MEN 2B (see Materials and methods) were screened for the MEN 2B-associated RET mutation M918T as previously described , and were found to have the wild-type sequence at codon 918. This analysis has been previously reported for two of these patients (MEN84(301) and MEN321: Eng et al., 1994 Eng et al., , 1996 Toogood et al., 1995) .
RET exon 15 was ampli®ed from duplicate constitutive DNA samples of patients and family members, and direct sequenced on both strands (see Materials and methods). Patient MEN84(301) has wild-type exon 15. Patients MEN413 and MEN231 have the heterozygous two-base substitution GCT (A)?TTT (F) at codon 883 ( Figure 1 ). This sequence variant was absent from both parents of patient MEN413, and from both parents and the unaected sister of patient MEN231. Hence this sequence variant represents a de novo RET mutation associated with two cases of MEN 2B.
This sequence variant was con®rmed by restriction endonuclease digestion in two ways. Firstly, the variant (GCT GAG?TTT GAG) removes a DdeI site (CTNAG). Screening the exon 15 amplicon of patients and family members for the loss of the DdeI site con®rmed the sequence data ( Figure 2a) . Secondly, as two-base substitutions are uncommon and the loss of DdeI depends only on the substitution of one base, we designed a strategy to be certain that the variant seen represented a genuine two-base substitution and was not a sequencing artefact. A second round of exon 15 PCR ampli®cation was performed in which the forward primer was replaced with a 33 base primer (see Materials and methods) which alters the sequence immediately upstream of codon 883 to create a SspI site (AATATT) only in the presence of the two-base substitution. Digestion of the 139 bp amplicon from patients MEN413 and MEN231 with SspI yields a 106 bp product indicating that the variant is indeed the two-base substitution (Figure 2b ).
Discussion
Germline mutation analysis of RET has been reported in 80 cases of MEN 2B, including the cases described here. Seventy-®ve of these 80 have an identical mutation, M918T. We have analysed three of the remaining ®ve cases, and have identi®ed the mutation A883F in two of these. Both are de novo cases of MEN 2B, and in each case the A883F mutation is a de novo RET mutation not present in either parent. This is very strong evidence to suggest that A883F is the disease causing mutation in these patients. In the third case, we have previously reported ®nding no abnormality on direct sequencing of exons 2 to 20 including exonintron boundaries and the 3' alternative splice junction of RET (Toogood et al., 1995) ; and here we con®rm that the A883F mutation is absent. This suggests that other RET mutations, or mutations in other genes, are able to cause MEN 2B.
Clinically the patients with the A883F mutation have no features to distinguish them from the 94% of MEN 2B patients in which the disease-causing mutation is M918T. The A883F mutation results Ethidium bromide-stained agarose gel of SspI digestions (+) and mock-digested (7) exon 15 amplicons (primers E15-SspI to E15-r2 from a de novo MEN 2B patient (MEN231) and an unaected family member (control). The amplicon (139 bp) from the mutant allele is digested to give a 106 bp product in the MEN 2B patient from a two base substitution, and this may account for its rarity relative to the M918T, which results from a single base substitution. In clinical management, mutation analysis of cases with an MEN 2B phenotype should start with a search for the M918T mutation, and if this is negative, for A883F. Cases with a well-attested phenotype who are negative for both mutations should be analysed further for mutations in other regions of RET.
There are two aspects of the MEN 2B syndrome: tumour formation and disordered development. The tumours are similar to those seen in MEN 2A, and are generally ascribed to consitutive activation of the RET kinase; whereas the developmental abnormalities are speci®c to MEN 2B and are therefore attributed to the altered substrate speci®city of the tyrosine kinase which results from the M918T mutation. The M918T mutation characteristic of MEN 2B also occurs frequently as a somatic mutation in sporadic MTC (approximately 40%), but the cysteine codon mutations characteristic of MEN 2A are rare. The explanation for this is unclear, but is also speculatively ascribed to the altered substrate speci®city of the M918T mutation. Although the A883F mutation has been reported in sporadic MTC, it is uncommon (four of 111 analysed; Eng and Mulligan, 1997; Marsh et al., 1996) . Whether this lower frequency re¯ects a dierence in the properties of the mutation, or merely the requirement for a two-base substitution, remains to be seen.
The MEN 2B mutations M918T and A883F lie in the distal half of the split kinase domain, either side of the highly conserved`activation loop' which is seen in receptor and non-receptor tyrosine kinases (Figure 3) . Studies of the insulin receptor kinase and FGFR1 have indicated that phosphorylation of two tyrosine residues in the`activation loop' is essential for activation of the kinase domain (Mohammadi et al., 1996a,b; Zhang et al., 1991; Ellis et al., 1986) . One of these two tyrosine residues is conserved at the equivalent position (Y905) in RET. Mutations in the`activation loop' of other receptor tyrosine kinases (D816V in c-kit and K650E in FGFR3; Figure 3 ) have been demonstrated to cause ligand-independent activation. Further receptor tyrosine kinase mutations in this region (D820G in c-kit and V1238I, D1246N, D1246H, Y1248C, Y1248H, M1268T in c-met; Figure 3 ) are thought to be activating. The FGFR3 K650E mutation has been suggested to alter conformation of the`activation loop' and stabilise it in a non-inhibitory conformation such that the dimerisation-induced phosphorylation of the two tyrosine residues in this region is no longer required for activation (Webster et al., 1996; Mohammadi et al., 1996a,b) . If this model can be extended to RET, phosphorylation of Y905 following dimerisation (by ligand or MEN 2A/FMTC cysteine codon mutation) would be required for kinase activity, however phosphorylation of Y905 would not be required for the activity of MEN 2B mutants. In accordance with this model, introduction of the mutation Y905?F abolishes MEN2A-RET activity, but not M918T-RET activity (Iwashita et al., 1996) .
The M918T mutation lies within the substrate binding pocket of the tyrosine kinase domain (Carlson et al., 1995; Hanks et al., 1988) , and whereas a M residue is seen at the equivalent position in most (Piao et al., 1996; Pignon et al., 1997) ; FGFR3: K650E in thanatophoric dysplasia type II (Webster et al., 1996) ; c-met: V1238I, D1246N and Y1248C in familial renal carcinoma and D1246H, Y1248H and M1268T in sporadic renal carcinoma (Schmidt et al., 1997) ; RET: M918T and A883F in MEN 2B). The position of the catalytic and activation loops is shown, and Y residues believed to be involved in activation are marked * (Webster et al., 1996; Mohammadi et al., 1996a,b) . Roman numerals indicate the position of the subdomains described by Hanks et al. (1988) receptor tyrosine kinases, a T is seen in most cytoplasmic tyrosine kinases. Hence it has been predicted that the substrate binding pocket of M918T-RET will be altered so as to prefer the substrates of cytoplasmic kinases. And indeed the M918T-RET kinase domain does phosphorylate synthetic peptide substrates of cytoplasmic kinases more eciently than the wild-type kinase domain (Songyang et al., 1995) . In addition, changes in M918T-RET autophosphorylation have been observed (Santoro et al., 1995; Liu et al., 1996) . The A883F mutation also lies within a region involved in substrate recognition (Hanks et al., 1988) , but the F residue is not seen in cytoplasmic kinases, and in fact a F residue at the equivalent position is very uncommon in tyrosine kinases. If the developmental abnormalities seen in MEN 2B are due to substrate speci®city changes, one would expect that the changes caused by the M918T and A883F mutations would be closely similar. A comparison of the substrate speci®cities of the two mutations should point to biologically relevant changes. For example, it will be interesting to determine if the A883F mutant shares with the M918T mutant reduced phosphorylation of the Grb2 docking site Y1096 (Liu et al., 1996) , and increased ability to phosphorylate the optimal synthetic substrates of src and abl (Songyang et al., 1995) .
Materials and methods

Patients
Patient MEN413 is a female. She underwent surgery to remove bilateral MTC and pheochromocytoma. She has multiple mucosal neuromata involving the tongue, thickened lips, a long thin body shape and lax joints. Slit lamp examination has indicated that she has thickened corneal nerves. Neither parent shows any clinical signs or symptoms of MEN 2B, and consequently this patient is a de novo case of MEN 2B.
Patient MEN231 is a female. She underwent surgery to remove bilateral MTC. She has multiple mucosal neuromata involving the tongue, bowel, lips, and eylids, and a long thin body shape. Neither parent nor a sister show any clinical signs or symptoms of MEN 2B, and consequently this patient is a de novo case of MEN 2B.
Patient MEN84(301) is a male aected member of the MEN 2B family described previously in detail (Toogood et al., 1995) . He underwent surgery to remove bilateral MTC and pheochromocytoma. He has Marfanoid body habitus, high arched palate, pes cavus, kyphoscoliosis and multiple mucosal neuromas.
PCR ampli®cation of RET exon 15
Genomic DNA was extracted from peripheral blood leukocytes using standard procedures. 100 ng of genomic DNA was used in a 50 ml PCR reaction using intronic primers E15-f1 and E15-r1. 1 ml of this reaction was used in a 100 ml PCR reaction using intronic primers E15-f2 and E15-r2, which are internal to the primers used in the ®rst round ampli®cation. 1 ml of the ®rst round reaction was also used in a 100 ml PCR reaction using the mutagenic exonic primer E15-SspI and E15-r2.
Red Hot DNA polymerase (Advanced Biotechnologies) was used in the buer supplied by the manufacturer containing 200 mM dNTPs and 1 mM each primer for 40 cycles of ampli®cation at one minute each of 958C, 588C and 728C.
Sequencing of RET exon 15
E15-f2 to E15-r2 PCR products were resolved on 2% low melting point agarose gels, the amplicon excised and extracted using the Wizard PCR Prep kit (Promega). Sequencing with primers E15-f2 and E15-r2 was performed with the AmpliCycle kit (Perkin Elmer).
Restriction endonuclease digestion
E15-f2 to E15-r2, and E15-SspI to E15-r2 PCR reactions were extracted with an equal volume of phenol, followed by an equal volume of chloroform, and then ethanol pecipitated.
Approximately 0.5 mg of E15-f2 to E15-r2 amplicon was digested with DdeI (New England Biolabs) following the manufacturer's recommendations. The wild-type amplicon (175 bp) is digested to give 105 bp and 70 bp products. The mutation GCT GAG?TTT GAG removes a DdeI site (CTNAG).
Approximately 0.5 mg of E15-SspI to E15-r2 amplicon was digested with SspI (New England Biolabs) following the manufacturer's recommendations. The wild-type amplicon is not digested by this endonuclease. However, the E15-SspI oligonucleotide alters the sequence immediately upstream of codon 883 to create a SspI site (AATATT) in the presence of the codon 883 GAG?TTT mutation. Digestion of the 139 bp amplicon yields a 106 bp product in the presence of this mutation.
Products of restriction digestion were resolved on 3% agarose gels stained with ethidium bromide, illuminated with u.v. light and the image captured with a BioRad Gel Doc 1000.
Primer sequences
Intronic primers 5' to exon 15 (E15-f1, E15-f2) and 3' to exon 15 (E15-r1, E15-r2) are shown below and were designed from the intronic sequences in GenBank (accession numbers U11508 and U11528). Exonic primer E15-SspI was designed to the human RET cDNA sequence with the underlined bases replacing GG. 
